GALDERMA GROUP AG (1GALD.MI) Stock Fundamental Analysis
Europe - BIT:1GALD - CH1335392721 - Common Stock
162 EUR
+162 (+Infinity%)
1GALD gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 54 industry peers in the Pharmaceuticals industry. 1GALD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, 1GALD is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
1GALD had positive earnings in the past year.
1GALD had a positive operating cash flow in the past year.
1.2 Ratios
With a Return On Assets value of 1.83%, 1GALD perfoms like the industry average, outperforming 40.74% of the companies in the same industry.
1GALD has a Return On Equity of 2.97%. This is comparable to the rest of the industry: 1GALD outperforms 40.74% of its industry peers.
1GALD's Return On Invested Capital of 4.56% is in line compared to the rest of the industry. 1GALD outperforms 42.59% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 1GALD is significantly below the industry average of 14.87%.
The 3 year average ROIC (3.87%) for 1GALD is below the current ROIC(4.56%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.83% | ||
| ROE | 2.97% | ||
| ROIC | 4.56% |
ROA(3y)0.19%
ROA(5y)N/A
ROE(3y)-0.1%
ROE(5y)N/A
ROIC(3y)3.87%
ROIC(5y)N/A
1.3 Margins
The Profit Margin of 1GALD (5.20%) is comparable to the rest of the industry.
Looking at the Operating Margin, with a value of 15.20%, 1GALD is in line with its industry, outperforming 46.30% of the companies in the same industry.
1GALD's Operating Margin has improved in the last couple of years.
1GALD's Gross Margin of 69.48% is in line compared to the rest of the industry. 1GALD outperforms 50.00% of its industry peers.
In the last couple of years the Gross Margin of 1GALD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.2% | ||
| PM (TTM) | 5.2% | ||
| GM | 69.48% |
OM growth 3Y14.42%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.24%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so 1GALD is destroying value.
1GALD has about the same amout of shares outstanding than it did 1 year ago.
Compared to 1 year ago, 1GALD has an improved debt to assets ratio.
2.2 Solvency
1GALD has an Altman-Z score of 6.73. This indicates that 1GALD is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.73, 1GALD belongs to the top of the industry, outperforming 90.74% of the companies in the same industry.
1GALD has a debt to FCF ratio of 12.94. This is a negative value and a sign of low solvency as 1GALD would need 12.94 years to pay back of all of its debts.
1GALD has a worse Debt to FCF ratio (12.94) than 68.52% of its industry peers.
1GALD has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.35, 1GALD is doing good in the industry, outperforming 62.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 12.94 | ||
| Altman-Z | 6.73 |
ROIC/WACC0.91
WACC5.02%
2.3 Liquidity
A Current Ratio of 1.21 indicates that 1GALD should not have too much problems paying its short term obligations.
1GALD has a worse Current ratio (1.21) than 64.81% of its industry peers.
A Quick Ratio of 0.94 indicates that 1GALD may have some problems paying its short term obligations.
1GALD's Quick ratio of 0.94 is in line compared to the rest of the industry. 1GALD outperforms 46.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 0.94 |
3. Growth
3.1 Past
1GALD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 2757.69%, which is quite impressive.
Looking at the last year, 1GALD shows a quite strong growth in Revenue. The Revenue has grown by 8.63% in the last year.
Measured over the past years, 1GALD shows a quite strong growth in Revenue. The Revenue has been growing by 8.83% on average per year.
EPS 1Y (TTM)2757.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%312.59%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y8.83%
Revenue growth 5YN/A
Sales Q2Q%11.28%
3.2 Future
Based on estimates for the next years, 1GALD will show a very strong growth in Earnings Per Share. The EPS will grow by 37.32% on average per year.
1GALD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.63% yearly.
EPS Next Y66.53%
EPS Next 2Y55.18%
EPS Next 3Y48.05%
EPS Next 5Y37.32%
Revenue Next Year17.07%
Revenue Next 2Y16.99%
Revenue Next 3Y16.68%
Revenue Next 5Y14.64%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 118.25, the valuation of 1GALD can be described as expensive.
1GALD's Price/Earnings ratio is a bit more expensive when compared to the industry. 1GALD is more expensive than 64.81% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.34, 1GALD is valued quite expensively.
With a Price/Forward Earnings ratio of 41.89, 1GALD can be considered very expensive at the moment.
1GALD's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. 1GALD is more expensive than 66.67% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 34.43. 1GALD is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 118.25 | ||
| Fwd PE | 41.89 |
4.2 Price Multiples
72.22% of the companies in the same industry are cheaper than 1GALD, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, 1GALD is valued a bit more expensive than the industry average as 68.52% of the companies are valued more cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 209.16 | ||
| EV/EBITDA | 48.4 |
4.3 Compensation for Growth
1GALD's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as 1GALD's earnings are expected to grow with 48.05% in the coming years.
PEG (NY)1.78
PEG (5Y)N/A
EPS Next 2Y55.18%
EPS Next 3Y48.05%
5. Dividend
5.1 Amount
With a yearly dividend of 0.04%, 1GALD is not a good candidate for dividend investing.
1GALD's Dividend Yield is slightly below the industry average, which is at 2.89.
Compared to an average S&P500 Dividend Yield of 2.36, 1GALD's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.04% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr YearsN/A
Div Non Decr YearsN/A
5.3 Sustainability
DPN/A
EPS Next 2Y55.18%
EPS Next 3Y48.05%
BIT:1GALD (11/5/2025, 7:00:00 PM)
162
+162 (+Infinity%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners29.71%
Inst Owner ChangeN/A
Ins Owners1.15%
Ins Owner ChangeN/A
Market Cap38.49B
Revenue(TTM)4.69B
Net Income(TTM)231.00M
Analysts82.11
Price Target169.88 (4.86%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.04% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 118.25 | ||
| Fwd PE | 41.89 | ||
| P/S | 10.03 | ||
| P/FCF | 209.16 | ||
| P/OCF | 91.29 | ||
| P/B | 5.72 | ||
| P/tB | N/A | ||
| EV/EBITDA | 48.4 |
EPS(TTM)1.37
EY0.85%
EPS(NY)3.87
Fwd EY2.39%
FCF(TTM)0.77
FCFY0.48%
OCF(TTM)1.77
OCFY1.1%
SpS16.15
BVpS28.33
TBVpS-7.88
PEG (NY)1.78
PEG (5Y)N/A
Graham Number29.55
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.83% | ||
| ROE | 2.97% | ||
| ROCE | 6.09% | ||
| ROIC | 4.56% | ||
| ROICexc | 4.76% | ||
| ROICexgc | 74.78% | ||
| OM | 15.2% | ||
| PM (TTM) | 5.2% | ||
| GM | 69.48% | ||
| FCFM | 4.8% |
ROA(3y)0.19%
ROA(5y)N/A
ROE(3y)-0.1%
ROE(5y)N/A
ROIC(3y)3.87%
ROIC(5y)N/A
ROICexc(3y)4.03%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)5.17%
ROCE(5y)N/A
ROICexgc growth 3Y-74.52%
ROICexgc growth 5YN/A
ROICexc growth 3Y23.71%
ROICexc growth 5YN/A
OM growth 3Y14.42%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.24%
GM growth 5YN/A
F-Score7
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 12.94 | ||
| Debt/EBITDA | 2.82 | ||
| Cap/Depr | 93.86% | ||
| Cap/Sales | 6.19% | ||
| Interest Coverage | 2.36 | ||
| Cash Conversion | 50.41% | ||
| Profit Quality | 92.21% | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 0.94 | ||
| Altman-Z | 6.73 |
F-Score7
WACC5.02%
ROIC/WACC0.91
Cap/Depr(3y)68.86%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.69%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2757.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%312.59%
EPS Next Y66.53%
EPS Next 2Y55.18%
EPS Next 3Y48.05%
EPS Next 5Y37.32%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y8.83%
Revenue growth 5YN/A
Sales Q2Q%11.28%
Revenue Next Year17.07%
Revenue Next 2Y16.99%
Revenue Next 3Y16.68%
Revenue Next 5Y14.64%
EBIT growth 1Y10.98%
EBIT growth 3Y24.52%
EBIT growth 5YN/A
EBIT Next Year35.91%
EBIT Next 3Y30.91%
EBIT Next 5Y25.87%
FCF growth 1Y1590.48%
FCF growth 3Y46.53%
FCF growth 5YN/A
OCF growth 1Y195.04%
OCF growth 3Y35.61%
OCF growth 5YN/A
GALDERMA GROUP AG / 1GALD.MI FAQ
What is the ChartMill fundamental rating of GALDERMA GROUP AG (1GALD.MI) stock?
ChartMill assigns a fundamental rating of 4 / 10 to 1GALD.MI.
What is the valuation status of GALDERMA GROUP AG (1GALD.MI) stock?
ChartMill assigns a valuation rating of 1 / 10 to GALDERMA GROUP AG (1GALD.MI). This can be considered as Overvalued.
Can you provide the profitability details for GALDERMA GROUP AG?
GALDERMA GROUP AG (1GALD.MI) has a profitability rating of 3 / 10.
Can you provide the financial health for 1GALD stock?
The financial health rating of GALDERMA GROUP AG (1GALD.MI) is 4 / 10.